Business
Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients
Shares of Sun Pharma rose 5 percent intraday on Friday after receiving approval from the Indian drug regulator for clinical trial of its drug on COVID-19 patients.
Reuters Last Updated:May 31, 2020 20:01:29 IST 
Bengaluru: Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.
“Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany,” the company said in a statement.
Click here to follow LIVE updates on coronavirus outbreak
Related Articles
10 ways you can help children with intellectual disabilities during the COVID-19 pandemic
Coronavirus India Roundup, May 8: PPE created by Navy gets approved, Indians evacuated from Abu Dhabi, Dhaka, Singapore
The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.
Shares of Sun Pharma rose 5 percent intraday on Friday after receiving approval from the Indian drug regulator for clinical trial of its drug on COVID-19 patients.